Acellular Pertussis Vaccine Effectiveness Over Time
- PMID: 31182549
- PMCID: PMC6615519
- DOI: 10.1542/peds.2018-3466
Acellular Pertussis Vaccine Effectiveness Over Time
Abstract
Objectives: To determine pertussis risk by diphtheria-tetanus-acellular pertussis (DTaP) vaccination status and time since last DTaP dose.
Methods: Children born at Kaiser Permanente Northern California between 1999 and 2016 were followed from 3 months of age until they tested positive for pertussis; disenrolled from Kaiser Permanente Northern California; received the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed vaccine; turned 11 years of age, or the end of the study period. DTaP vaccination status was categorized on the basis of the number of doses received in relation to the number of doses expected according to the Advisory Committee on Immunization Practice-recommended ages.
Results: Among 469 982 children ages 3 months to 11 years, we identified 738 pertussis cases. A total of 99 cases were unvaccinated, 36 were undervaccinated, 515 were fully vaccinated, and 88 were fully vaccinated plus 1 dose. Pertussis risk was 13 times higher among unvaccinated (adjusted hazard ratio [aHR] = 13.53; 95% confidence interval [CI] 10.64-17.21) compared with fully vaccinated children and 1.9 times higher (aHR = 1.86; 95% CI 1.32-2.63) among undervaccinated children. Among vaccinated children ages 19 to <84 months, pertussis risk was 5 times higher (aHR = 5.04; 95% CI 1.84-13.80) ≥3 years vs <1 year after vaccination. Among children ages 84 to 132 months, risk was 2 times higher (aHR = 2.32; 95% CI 0.97-5.59) ≥6 years vs <3 years after vaccination.
Conclusions: Undervaccinated and especially unvaccinated children were at greater risk of pertussis. However, most pertussis cases occurred among children age-appropriately vaccinated who were further away from their last DTaP dose, suggesting that suboptimal vaccine effectiveness played a major role in recent pertussis epidemics.
Copyright © 2019 by the American Academy of Pediatrics.
Conflict of interest statement
POTENTIAL CONFLICT OF INTEREST: Dr Klein reports potential conflicts of interest relevant to this article: the pertussis vaccines purchased by Kaiser Permanente Northern California, which are the focus of this study, were manufactured by GlaxoSmithKline and Sanofi Pasteur; the others authors have indicated they have no potential conflicts of interest to disclose.
Comment in
-
Challenges to Pertussis Control.Pediatrics. 2019 Jul;144(1):e20191276. doi: 10.1542/peds.2019-1276. Epub 2019 Jun 10. Pediatrics. 2019. PMID: 31182551 No abstract available.
Similar articles
-
Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.Pediatrics. 2005 Aug;116(2):e285-94. doi: 10.1542/peds.2004-2759. Pediatrics. 2005. PMID: 16061582
-
Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.Pediatrics. 2001 Nov;108(5):E81. doi: 10.1542/peds.108.5.e81. Pediatrics. 2001. PMID: 11694665 Clinical Trial.
-
Waning Tdap Effectiveness in Adolescents.Pediatrics. 2016 Mar;137(3):e20153326. doi: 10.1542/peds.2015-3326. Epub 2016 Feb 5. Pediatrics. 2016. PMID: 26908667
-
Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2008 May 30;57(RR-4):1-51. MMWR Recomm Rep. 2008. PMID: 18509304 Review.
-
New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).Ann Pharmacother. 2010 Mar;44(3):515-23. doi: 10.1345/aph.1M468. Ann Pharmacother. 2010. PMID: 20197476 Review.
Cited by
-
A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis.NPJ Vaccines. 2024 Oct 16;9(1):190. doi: 10.1038/s41541-024-00990-1. NPJ Vaccines. 2024. PMID: 39406780 Free PMC article.
-
Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussis.Nat Commun. 2024 Mar 8;15(1):2133. doi: 10.1038/s41467-024-46560-w. Nat Commun. 2024. PMID: 38459022 Free PMC article.
-
Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records.BMJ. 2023 Nov 8;383:e076321. doi: 10.1136/bmj-2023-076321. BMJ. 2023. PMID: 37940142 Free PMC article.
-
The association between vaccine hesitancy and pertussis: a systematic review and meta-analysis.Ital J Pediatr. 2023 Jul 13;49(1):81. doi: 10.1186/s13052-023-01495-8. Ital J Pediatr. 2023. PMID: 37443026 Free PMC article.
-
Whole-Genome Analysis of Bordetella pertussis MT27 Isolates from School-Associated Outbreaks: Single-Nucleotide Polymorphism Diversity and Threshold of the Outbreak Strains.Microbiol Spectr. 2023 Jun 15;11(3):e0406522. doi: 10.1128/spectrum.04065-22. Epub 2023 May 16. Microbiol Spectr. 2023. PMID: 37191540 Free PMC article.
References
-
- Hegerle N, Guiso N. Epidemiology of whooping cough & typing of Bordetella pertussis. Future Microbiol. 2013;8(11):1391–1403 - PubMed
-
- Cherry JD. Epidemic pertussis in 2012–the resurgence of a vaccine-preventable disease. N Engl J Med. 2012;367(9):785–787 - PubMed
-
- Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981;68(5):650–660 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
